Why the focal defect and OA distinction decides candidacy

The question that determines ChondroFiller candidacy is not 'do I have cartilage damage?' — most patients seeking this assessment do. The question is: what kind?

A focal articular cartilage defect is a discrete, contained area of damage within an otherwise functional joint, typically caused by a single injury or a condition such as osteochondritis dissecans. Osteoarthritis is categorically different: a progressive, multi-compartmental degenerative process involving widespread cartilage loss, subchondral bone remodelling, osteophyte formation, and chronic synovial inflammation.

This distinction is not administrative. It is mechanistic. ChondroFiller works by placing an acellular collagen scaffold into the defect void, where it polymerises in situ and acts as a chemotactic matrix — recruiting the patient's own progenitor cells from the surrounding tissue to migrate in and support endogenous repair. That process depends entirely on the local joint environment. Healthy surrounding cartilage and functional synovial biology must be present for cell migration and matrix integration to occur.

In advanced or generalised osteoarthritis, that environment no longer exists. Chronic inflammation, depleted progenitor cell populations, and structurally compromised surrounding tissue mean the scaffold has no viable anchor and no adequate cell reservoir to draw from. This is why generalised or multi-compartmental OA is treated as a strict contraindication — not a relative caution to weigh against other factors, but a biological threshold below which the treatment cannot work as intended.

How ChondroFiller works as an injectable collagen scaffold

ChondroFiller® liquid is a CE-marked Class III medical device manufactured by Meidrix Biomedicals GmbH in Germany — a sterile, acellular injectable scaffold derived from murine (rat) Type I collagen. Its composition matters for two practical reasons: the murine origin means patients are screened for collagen or rat-protein allergy before treatment, and its cell-free design defines exactly how the scaffold works.

Delivered under ultrasound guidance as an outpatient injection directly into the cartilage defect, the liquid collagen polymerises in situ within 3–5 minutes, forming a porous three-dimensional gel that fills and conforms to the void. No incisions are involved; the procedure takes place in a clinic setting.

What follows is the process described clinically as acellular matrix-induced chondrogenesis. The gel itself contains no cells, no stem cells, and no added growth factors. Instead, it acts as a chemotactic scaffold — a structured environment that signals to the patient's own progenitor cells residing in the surrounding synovium and subchondral bone, drawing them to migrate into the defect site. Once recruited, those cells begin to differentiate and deposit hyaline-like cartilage matrix, a process that unfolds over 6–12 months.

The patient's own biology does the repair. The scaffold supplies the architecture and the signalling environment; the host tissue supplies the cellular machinery. This is why 'supports the body's own repair processes' describes the mechanism more accurately than 'regrows cartilage' — the regenerative capacity originates from within the joint itself, not from the injected device.

Candidacy criteria for ChondroFiller injection

Specialists assessing a patient for ChondroFiller injection look at the joint picture as a whole, not at any single factor in isolation. Age alone is not an exclusion criterion, and a broad diagnosis of osteoarthritis is not automatically disqualifying — what matters is whether the damage is focal and the surrounding joint environment is intact enough to support the scaffold's action.

What typically supports inclusion

• A focal chondral or osteochondral defect, commonly up to approximately 6 cm², within an otherwise functional joint
• Stable joint mechanics — ligamentous integrity and reasonable alignment
• No active inflammatory or systemic joint disease
• No allergy or hypersensitivity to collagen or murine (rat) protein

What leads to exclusion

• Advanced or multi-compartmental osteoarthritis, where generalised joint degradation means the biological environment cannot sustain the scaffold
• Inflammatory arthropathies such as rheumatoid arthritis or psoriatic arthritis — immune-mediated inflammation disrupts scaffold integration even when cartilage loss appears localised on imaging
• Active local or systemic infection
• Tumour near the joint
• Pregnancy or breastfeeding
• Malignant, haematopoietic, or relevant neurological disorders
• Elevated bleeding risk

Multi-compartmental arthrosis and inflammatory arthropathies share the same underlying reason for exclusion: both disrupt the local biology on which the scaffold depends.

From a safety perspective, the published record across more than 19,000 cases shows a complication rate of approximately 0% and a reoperation rate of roughly 3–8% — a profile that compares favourably with microfracture (reoperation rates reported at up to 41%) and ACI/MACI (complication rates up to 17%). Candidacy within these parameters is confirmed at consultation following imaging review.

Why advanced OA rules out ChondroFiller

The scaffold's action depends entirely on what the surrounding joint can offer. Each contraindication identified in assessment maps onto a specific way the local biology becomes unable to sustain that action.

In advanced or multi-compartmental OA, chronically elevated inflammatory mediators — including interleukins and matrix metalloproteinases — create a catabolic environment in which the collagen gel is degraded before meaningful cell recruitment can occur. Equally important, the progenitor cells the scaffold signals to are drawn from the surrounding cartilage and synovium. Where those tissues have been progressively lost or remodelled, the reservoir that the scaffold depends on is simply no longer there in sufficient quantity.

Subchondral bone remodelling in advanced OA compounds the problem. The scaffold requires structurally viable tissue at its margins to remain seated and to provide an interface for migrating cells. When subchondral bone has sclerosed and the surrounding cartilage has degenerated across multiple compartments, those anchor conditions are absent.

Inflammatory arthropathies such as rheumatoid or psoriatic arthritis follow the same logic. Active immune-mediated inflammation — even when imaging shows a localised lesion — floods the joint with cytokines that can interfere with scaffold integration and suppress the chondrogenic differentiation the mechanism relies on. Active infection adds a further and more immediate risk: bacteria can directly degrade the collagen matrix before it has any opportunity to function.

The downstream consequence for untreated focal defects is worth noting. Exposed subchondral bone alters load distribution across the joint, and some evidence suggests this initiates the degenerative cascades that lead to OA over time. That progression is itself a clinical argument for assessing eligible patients promptly rather than monitoring to a threshold.

Older patients with background wear and a discrete symptomatic lesion

Not every patient presenting with knee pain falls cleanly on one side of the focal-defect–OA divide. A patient in their 60s or 70s who has been told they need a knee replacement may carry a background of mild diffuse wear and simultaneously have a discrete, heavily symptomatic lesion that is contributing disproportionately to their pain. For this group, the broad label of osteoarthritis does not automatically decide whether ChondroFiller is appropriate.

What the specialist is looking for in this situation is imaging evidence that the symptomatic lesion is genuinely focal — contained, with surrounding cartilage that retains enough structural integrity to support the scaffold's action. MRI is central to this assessment, confirming both the lesion's boundaries and the viability of adjacent tissue. A diffuse pattern of wear across multiple compartments, even in a patient who appears otherwise well, shifts the picture towards the exclusions described in the previous section.

Where imaging does confirm a focal, contained lesion in a joint that otherwise meets the biological threshold, ChondroFiller may be considered as a joint-preservation pathway — explicitly positioned as a pre-replacement option for patients with some salvageable cartilage, rather than a substitute for total knee replacement where cartilage is no longer viable. The question at consultation is not whether the patient has some degree of background wear, but whether a sufficient, localised opportunity exists for the scaffold to function.

Age is not a determining factor in itself. The decision rests on what imaging reveals about the specific lesion and the surrounding joint environment — which is why individual specialist assessment with MRI review is the only reliable way to clarify candidacy for this group.

Outcomes, access costs, and finding a UK specialist

Published clinical series report IKDC score improvements of approximately 30 points in the knee at 12 months, and MOCART MRI cartilage regeneration scores ranging from 70 to 87. Those are meaningful gains — but they come with an important qualification. The evidence base to date is primarily manufacturer-sponsored, large independent randomised controlled trials are lacking, and follow-up data beyond 12 to 24 months remain limited. Patients weighing ChondroFiller against established alternatives such as ACI/MACI or a watchful-waiting approach should factor that gap into the conversation with their specialist, rather than treating early outcomes as a settled long-term picture.

On access, the practical position in the UK is straightforward. ChondroFiller is a self-funded treatment, imported from Germany under individual patient prescription, priced from approximately £3,000 per box. It is not currently covered by the NHS, and neither Bupa nor AXA provides reimbursement — patients should confirm their funding position before booking a consultation. For those in the United States, the device does not hold FDA approval and is not available through that regulatory pathway.

Specialists offering ChondroFiller injection for focal cartilage defects practise across the UK. Search MSK is a directory where they can be located by region and clinical specialty — a practical starting point for anyone who wants to identify a clinician able to review their imaging and confirm whether they meet the candidacy criteria.